EU-European Union drug regulators have stated that cases of confirmed blood clots in blood vessels such as the brain after vaccination with the new coronavirus vaccine by American pharmaceutical giant Johnson & Johnson were "described as a rare side reaction." It should be done. "
On the other hand, he emphasizes that "the benefits of this vaccine outweigh the risks of side effects."
Vaccination with this vaccine has not started in earnest in Europe, but more than 7 million people have been vaccinated in the United States, and there are eight reports that blood clots have been confirmed in blood vessels of the brain after vaccination. One of them has died.
The EMA = European Medicines Agency, which conducted the survey, concluded on the 20th that "these cases should be described as a side reaction of a very rare vaccine."
It is a rare symptom that blood clots are formed while the number of platelets that play a role in blood clotting is reduced, which is similar to the case of blood clots reported after vaccination developed by British pharmaceutical giant AstraZeneca and others. ..
It is reasonable to assume that it is due to an immune reaction, but the detailed cause is unknown.
All eight cases were younger than 60 years and occurred within 3 weeks of vaccination, most of them female, but at this time it has not been confirmed whether the risk increases in any particular age group or gender.
According to the EMA, "the benefits of this vaccine outweigh the risk of side effects," and on the premise that vaccination will proceed, symptoms such as shortness of breath, chest pain, and swelling of the legs will be seen within 3 weeks after vaccination. In that case, it is necessary to see a medical institution immediately.
Johnson & Johnson "Caution to Healthcare Professionals"
Following the announcement of the EMA = European Medicines Agency, Johnson & Johnson issued a statement stating that "as a rare event that is harmful to health, healthcare professionals will be alerted to the diagnosis and coping strategies for thrombosis." I put it out.
In the statement, "Safety and security of product users is our number one priority. We believe in the benefits of a single vaccination and easy-to-transport vaccine. The fairness of cheap vaccines will continue. We will do our best to distribute the vaccine. "Keywords: